Captor Therapeutics announces participation in upcoming scientific, investor, and partnering conferences in October 2022
Wrocław, Poland, September 20, 2022. - Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company dedicated to the development of Targeted Protein Degradation (TPD)-based drugs for the treatment of cancer and autoimmune diseases, today announces that the company's team members will participate in the following conferences during October 2022:
- 4th Annual Protein Degradation & Targeting Undruggables European Congress, October 11th - 12th, 2022, Basel
Captor Therapeutics Chief Executive Officer Dr. Tom Shepherd will speak about the rationalization of molecular glue discovery on October 12th at 4:30 PM CEST. Registration for the conference is open here.
- BIO-Europe, October 24th - 26th, 2022, Leipzig
The Captor Therapeutics management team will hold in-person one-on-one meetings. Registration for the conference is open here.
- 5th Annual Targeted Protein Degradation Summit, October 25th - 28th, 2022, Boston
Captor Therapeutics scientists will present a poster during the poster session on October 27th. Registration for the conference is open here.
- ENA 2022, October 26th - 28th, 2022, Barcelona
Captor Therapeutics scientists will present a poster during the poster session on October 28th, entitled "Development of selective MCL-1 heterobifunctional degraders". Registration for the conference is open here.
To request a one-on-one meeting with the Captor Therapeutics management team, please contact us at firstname.lastname@example.org.
About Captor Therapeutics
Captor Therapeutics is a biopharmaceutical company dedicated to using targeted protein degradation (TPD) technology to discover and develop breakthrough drugs for diseases deemed as medically uncurable. TPD is a revolutionary approach to developing new drugs that can target new molecular targets considered "untreatable" using classical drug development methods and provide additional treatment options for diseases where existing drugs do not provide optimal medical benefit. Captor is currently developing treatments for undertreated serious conditions, including malignancies and autoimmune diseases.
For more information on Captor Therapeutics, visit: http://www.captortherapeutics.com
W celu uzyskania dalszych informacji prosimy o kontakt:
Polish Media and Investor relations:
Point of View
+48 694 400 787
International Investor Relations:
Guillaume van Renterghem
+41 (0)76 735 01 31